Bosakitug is under clinical development by Biosion and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bosakitug’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bosakitug overview
Bosakitug is under development for the treatment of atopic dermatitis (atopic eczema), asthma, chronic obstructive pulmonary disease and chronic sinusitis with nasal polyps. It is administered through subcutaneous route and acts by targeting thymic stromal lymphopoietin (TSLP). The therapeutic candidate is being developed based on H3 (high-throughput, high-content, high-efficiency) antibody platform and SynAb technology.
The therapeutic candidate was under development for the treatment of cat allergy.
Biosion overview
Biosion is a biotechnology company that discovers and develops biologics to treat immune and oncologic diseases. The company provides pipeline programs such as BSI-045B for Atopic Dermatitis and Asthma and BSI-060T for the treatment of solid tumor, BSI-585, BSI-04702 – Solid Tumors. Biosion’s lead asset, BSI-045B (anti-TSLP mAb) is in phase 1 clinical trials. It also offers technological platforms such as the H³ antibody discovery, SynTracer HT-endocytosis and Flexibody bispecific platforms to develop its products. The company has operations in Australia and the US. Biosion is headquartered in Nanjing, Jiangsu, China.
For a complete picture of Bosakitug’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
